SLC16A1 and glioblastoma: Numerous studies have found that knockdown or inhibition of MCT1 and/or MCT4 decreases lactate levels and tumor cell growth, migration, and invasion in vitro and in vivo for diverse cancers, including bladder cancer, breast cancer, colon cancer, glioblastoma, and liver cancer (89, 95–100).